Biohaven (BHVN) News
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.08+0.15 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BHVN news summary
We found 2 recent headlines mentioning Biohaven (BHVN): 2 in the past week and 2 in the past 30 days, most often from Seeking Alpha, PR Newswire. For price context, BHVN is up 1.26% at $12.08. The most recent story, "Biohaven licenses IgG degrader portfolio to Japan’s Ono", was published by Seeking Alpha on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Biohaven headlines
- Biohaven licenses IgG degrader portfolio to Japan’s OnoSeeking Alpha
- Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseOno will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain…PR Newswire